Literature DB >> 25445558

Lung cancer. How much platinum-based chemotherapy is enough in NSCLC?

Solange Peters1, Alex A Adjei2.   

Abstract

With no large randomized phase III trials to provide definitive answers, the ideal number of platinum-based chemotherapy cycles in patients with advanced non-small-cell lung cancer has long been unclear. Most guidelines recommend a maximum of 4–6 cycles. Rossi and colleagues now suggest that four chemotherapy cycles is the optimal regimen.

Entities:  

Mesh：

Year:  2014        PMID： 25445558     DOI： 10.1038/nrclinonc.2014.212

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  9 in total

1.  2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Authors:  Christopher G Azzoli; Sarah Temin; Giuseppe Giaccone
Journal:  J Oncol Pract       Date:  2011-11-29       Impact factor: 3.840

Review 2.  Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

Authors:  Yu Yang Soon; Martin R Stockler; Lisa M Askie; Michael J Boyer
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

3.  Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.

Authors:  I E Smith; M E O'Brien; D C Talbot; M C Nicolson; J L Mansi; T F Hickish; A Norton; S Ashley
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

4.  Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  M Reck; S Popat; N Reinmuth; D De Ruysscher; K M Kerr; S Peters
Journal:  Ann Oncol       Date:  2014-08-11       Impact factor: 32.976

5.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Authors:  Luis G Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

Review 6.  Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.

Authors:  Antonio Rossi; Paolo Chiodini; Jong-Mu Sun; Mary E R O'Brien; Christian von Plessen; Fernando Barata; Keunchil Park; Sanjay Popat; Bengt Bergman; Barbara Parente; Ciro Gallo; Cesare Gridelli; Francesco Perrone; Massimo Di Maio
Journal:  Lancet Oncol       Date:  2014-09-14       Impact factor: 41.316

7.  Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.

Authors:  R Rosell; U Gatzemeier; D C Betticher; U Keppler; H N Macha; R Pirker; P Berthet; J L Breau; P Lianes; M Nicholson; A Ardizzoni; A Chemaissani; J Bogaerts; G Gallant
Journal:  Ann Oncol       Date:  2002-10       Impact factor: 32.976

8.  Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.

Authors:  Joon Oh Park; Sang-We Kim; Jin Seok Ahn; Cheolwon Suh; Jung Shin Lee; Joung Soon Jang; Eun Kyung Cho; Sung Hyun Yang; Jin-Hyuk Choi; Dae Seog Heo; Suk Young Park; Sang Won Shin; Myung Ju Ahn; Jong Seok Lee; Young Ho Yun; Jae-Won Lee; Keunchil Park
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

9.  Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.

Authors:  C von Plessen; B Bergman; O Andresen; R M Bremnes; S Sundstrom; M Gilleryd; R Stephens; J Vilsvik; U Aasebo; S Sorenson
Journal:  Br J Cancer       Date:  2006-10-03       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.